Oguzhan Atay, PhD

Career

1. 2016 – now
   BillionToOne, Inc.src
   Co-Founder & CEO; director since 2016; Chair of the Board
   Took the company public on Nasdaq in November 2025 (4,551,100 Class A shares at $60.00)

Not located: Before 2016 only education is sourced: the years of his Stanford PhD and Princeton degree are not dated in any primary document searched (a search summary put the PhD in 2016 but no page carrying that date was located). BillionToOne is his only employer in the filings

Achievements

• Co-founded BillionToOne in 2016 and has led it since, co-developing its molecular counting platformsrc
• Took the company public in November 2025 at $60.00 a share, selling 4,551,100 new Class A sharessrc
• BillionToOne reported GAAP net income of $7.5m for FY2025, against net losses of $41.6m in FY2024 and $82.7m in FY2023src
• Holds 2,227,542 Class B shares (15 votes each) as of 2026-03-31, giving him 31.1% of the combined votesrc

Education

• Stanford University, PhD Biologysrc
• Princeton University, Bachelor's Molecular biology (minors in physics, computer science and applied mathematics)src

Background

• Family The 2026 proxy states there are no family relationships among any nominees, directors or executive officerssrc
• Family His spouse held 200,000 Class A shares at 2026-03-31 (beneficial ownership disclaimed); she sold under her own 10b5-1 plan alongside his sales and held 157,168 after 2026-09-14src
• Founder Co-founded the company with David Tsao, now President, CTO and director. The two hold all the Class B stock: 31.1% (Atay) and 32.2% (Tsao) of the combined vote at 2026-03-31. Class B converts to Class A seven years after the post-IPO charter, or earlier on a Class B majority vote, or after a founder leaves or diessrc
• Founder Exchanged 2,227,542 Class A shares for high-vote Class B shares at the IPO under an exchange agreement dated 2025-11-07, for no extra considerationsrc
• Other Sold 196,126 shares for about $5.0m ($25.49 a share) to affiliates of Libertus Capital in April 2022, a pre-IPO secondary on which the company waived its right of first refusal. Tsao made an identical salesrc
• Other Listed as a Colella Family Fellow on the Stanford Bio-X people pagessrc
• Other Has described his path from a small town in Turkey through Princeton and a Stanford PhD to founding BillionToOne in a two-part interview on The Biotech Startups Podcastsrc